<!-- Generated by pkgdown: do not edit by hand -->
<!DOCTYPE html>
<html>
  <head>
  <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<title>Create an Adverse Events (AET02) Table — t_ae • osprey</title>

<!-- jquery -->
<script src="https://code.jquery.com/jquery-3.1.0.min.js" integrity="sha384-nrOSfDHtoPMzJHjVTdCopGqIqeYETSXhZDFyniQ8ZHcVy08QesyHcnOUpMpqnmWq" crossorigin="anonymous"></script>
<!-- Bootstrap -->
<link href="https://maxcdn.bootstrapcdn.com/bootswatch/3.3.7/cerulean/bootstrap.min.css" rel="stylesheet" crossorigin="anonymous">

<script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha384-Tc5IQib027qvyjSMfHjOMaLkfuWVxZxUPnCJA7l2mCWNIpG9mGCD8wGNIcPD7Txa" crossorigin="anonymous"></script>

<!-- Font Awesome icons -->
<link href="https://maxcdn.bootstrapcdn.com/font-awesome/4.6.3/css/font-awesome.min.css" rel="stylesheet" integrity="sha384-T8Gy5hrqNKT+hzMclPo118YTQO6cYprQmhrYwIiQ/3axmI1hQomh7Ud2hPOy8SP1" crossorigin="anonymous">

<!-- clipboard.js -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/1.7.1/clipboard.min.js" integrity="sha384-cV+rhyOuRHc9Ub/91rihWcGmMmCXDeksTtCihMupQHSsi8GIIRDG0ThDc3HGQFJ3" crossorigin="anonymous"></script>

<!-- sticky kit -->
<script src="https://cdnjs.cloudflare.com/ajax/libs/sticky-kit/1.1.3/sticky-kit.min.js" integrity="sha256-c4Rlo1ZozqTPE2RLuvbusY3+SU1pQaJC0TjuhygMipw=" crossorigin="anonymous"></script>

<!-- pkgdown -->
<link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script>



<meta property="og:title" content="Create an Adverse Events (AET02) Table — t_ae" />

<meta property="og:description" content="t_ae returns adverse events according to STREAM format AET02" />
<meta name="twitter:card" content="summary" />

<meta name="robots" content="noindex">

<!-- mathjax -->
<script src='https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML'></script>

<!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->


  </head>

  <body>
    <div class="container template-reference-topic">
      <header>
      <div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">osprey</a>
        <span class="label label-danger" data-toggle="tooltip" data-placement="bottom" title="In-development package">0.1.0</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="../index.html">
    <span class="fa fa-home fa-lg"></span>
     
  </a>
</li>
<li>
  <a href="../reference/index.html">Reference</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Articles
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="../articles/osprey_teal.html">Using Osprey TLGs with teal</a>
    </li>
  </ul>
</li>
      </ul>
      
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://github.roche.com/Rpackages/osprey">
    <span class="fa fa-github"></span>
     
  </a>
</li>
      </ul>
      
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

      
      </header>

<div class="row">
  <div class="col-md-9 contents">
    <div class="page-header">
    <h1>Create an Adverse Events (AET02) Table</h1>
    
    <div class="hidden name"><code>t_ae.Rd</code></div>
    </div>

    <div class="ref-description">
    
    <p><code>t_ae</code> returns adverse events according to STREAM format AET02</p>
    
    </div>

    <pre class="usage"><span class='fu'>t_ae</span>(<span class='no'>class</span>, <span class='no'>term</span>, <span class='no'>id</span>, <span class='no'>col_by</span>, <span class='kw'>total</span> <span class='kw'>=</span> <span class='st'>"All Patients"</span>, <span class='kw'>sort_by</span> <span class='kw'>=</span> <span class='st'>"count"</span>,
  <span class='no'>...</span>)</pre>
    
    <h2 class="hasAnchor" id="arguments"><a class="anchor" href="#arguments"></a>Arguments</h2>
    <table class="ref-arguments">
    <colgroup><col class="name" /><col class="desc" /></colgroup>
    <tr>
      <th>class</th>
      <td><p>system organ class variable.</p></td>
    </tr>
    <tr>
      <th>term</th>
      <td><p>preferred term variable.</p></td>
    </tr>
    <tr>
      <th>id</th>
      <td><p>unique subject identifier variable. If a particular subject has no
adverse event then the subject <code>id</code> should be listed where
<code>class</code> and <code>term</code> should be set to missing (i.e. <code>NA</code>).</p></td>
    </tr>
    <tr>
      <th>col_by</th>
      <td><p>group variable that will be used for a column header. <code>col_by</code>
has to be a factor and can not be missing.</p></td>
    </tr>
    <tr>
      <th>total</th>
      <td><p>character string that will be used as a label for a column with
pooled total population, default here is "All Patients", if set to "NONE" then
the "All Patients" column is suppressed.</p></td>
    </tr>
    <tr>
      <th>sort_by</th>
      <td><p>character string that defines the ordering of the class and term
variables in the output table,
options: "alphabetical" or "count", default here is set to "count"</p></td>
    </tr>
    </table>
    
    <h2 class="hasAnchor" id="value"><a class="anchor" href="#value"></a>Value</h2>

    <p><code>rtable</code> object</p>
    

    <h2 class="hasAnchor" id="examples"><a class="anchor" href="#examples"></a>Examples</h2>
    <pre class="examples"><div class='input'><span class='co'># Simple example</span>
<span class='fu'>library</span>(<span class='no'>tibble</span>)
<span class='fu'>library</span>(<span class='no'>dplyr</span>)
<span class='fu'>library</span>(<span class='no'>rtables</span>)

<span class='no'>ASL</span> <span class='kw'>&lt;-</span> <span class='fu'><a href='http://www.rdocumentation.org/packages/tibble/topics/tibble'>tibble</a></span>(
  <span class='kw'>USUBJID</span> <span class='kw'>=</span> <span class='fu'>paste0</span>(<span class='st'>"id-"</span>, <span class='fl'>1</span>:<span class='fl'>10</span>),
  <span class='kw'>ARM</span> <span class='kw'>=</span> <span class='fu'>paste</span>(<span class='st'>"ARM"</span>, <span class='no'>LETTERS</span>[<span class='fu'>rep</span>(<span class='fu'>c</span>(<span class='fl'>1</span>,<span class='fl'>2</span>), <span class='fu'>c</span>(<span class='fl'>3</span>,<span class='fl'>7</span>))])
)


<span class='no'>ae_lookup</span> <span class='kw'>&lt;-</span> <span class='fu'><a href='http://www.rdocumentation.org/packages/tibble/topics/tribble'>tribble</a></span>(
~<span class='no'>CLASS</span>,         ~<span class='no'>TERM</span>,   ~<span class='no'>GRADE</span>,
<span class='st'>"cl A"</span>,   <span class='st'>"trm A_1/2"</span>,        <span class='fl'>1</span>,
<span class='st'>"cl A"</span>,   <span class='st'>"trm A_2/2"</span>,        <span class='fl'>2</span>,
<span class='st'>"cl B"</span>,   <span class='st'>"trm B_1/3"</span>,        <span class='fl'>2</span>,
<span class='st'>"cl B"</span>,   <span class='st'>"trm B_2/3"</span>,        <span class='fl'>3</span>,
<span class='st'>"cl B"</span>,   <span class='st'>"trm B_3/3"</span>,        <span class='fl'>1</span>,
<span class='st'>"cl C"</span>,   <span class='st'>"trm C_1/1"</span>,        <span class='fl'>1</span>
)

<span class='no'>AAE</span> <span class='kw'>&lt;-</span> <span class='fu'>cbind</span>(
  <span class='fu'><a href='http://www.rdocumentation.org/packages/tibble/topics/tibble'>tibble</a></span>(
    <span class='kw'>USUBJID</span> <span class='kw'>=</span> <span class='no'>ASL</span>$<span class='no'>USUBJID</span>[<span class='fu'>c</span>(<span class='fl'>2</span>,<span class='fl'>2</span>,<span class='fl'>2</span>,<span class='fl'>3</span>,<span class='fl'>3</span>,<span class='fl'>4</span>,<span class='fl'>4</span>,<span class='fl'>4</span>,<span class='fl'>4</span>,<span class='fl'>5</span>,<span class='fl'>6</span>,<span class='fl'>6</span>,<span class='fl'>7</span>,<span class='fl'>7</span>)]
  ),
  <span class='no'>ae_lookup</span>[<span class='fu'>c</span>(<span class='fl'>1</span>,<span class='fl'>1</span>,<span class='fl'>2</span>,<span class='fl'>6</span>,<span class='fl'>4</span>,<span class='fl'>2</span>,<span class='fl'>2</span>,<span class='fl'>3</span>,<span class='fl'>4</span>,<span class='fl'>2</span>,<span class='fl'>1</span>,<span class='fl'>5</span>,<span class='fl'>4</span>,<span class='fl'>6</span>),]
)

<span class='no'>ANL</span> <span class='kw'>&lt;-</span> <span class='fu'><a href='http://dplyr.tidyverse.org/reference/join.html'>left_join</a></span>(<span class='no'>ASL</span>, <span class='no'>AAE</span>, <span class='kw'>by</span> <span class='kw'>=</span> <span class='st'>"USUBJID"</span>)

<span class='no'>tbl</span> <span class='kw'>&lt;-</span> <span class='fu'>t_ae</span>(
  <span class='kw'>class</span> <span class='kw'>=</span> <span class='no'>ANL</span>$<span class='no'>CLASS</span>,
  <span class='kw'>term</span> <span class='kw'>=</span>  <span class='no'>ANL</span>$<span class='no'>TERM</span>,
  <span class='kw'>id</span> <span class='kw'>=</span> <span class='no'>ANL</span>$<span class='no'>USUBJID</span>,
  <span class='kw'>col_by</span> <span class='kw'>=</span> <span class='fu'>factor</span>(<span class='no'>ANL</span>$<span class='no'>ARM</span>),
  <span class='kw'>total</span> <span class='kw'>=</span> <span class='st'>"All Patients"</span>,
)

<span class='no'>tbl</span></div><div class='output co'>#&gt; MedDRA System Organ Class                                            ARM A               ARM B            All Patients
#&gt;   MedDRA Preferred Term                                              (N=3)               (N=7)               (N=10)   
#&gt; ----------------------------------------------------------------------------------------------------------------------
#&gt; Total number of patients with at least one adverse event           2 (66.7%)           4 (57.1%)            6 (60%)   
#&gt; 
#&gt; Overall total number of events                                         5                   9                   14     
#&gt; cl A
#&gt;   Total number of patients with at least one adverse event         1 (33.3%)           3 (42.9%)            4 (40%)   
#&gt; 
#&gt;   Total number of events                                               3                   4                   7      
#&gt; 
#&gt;   trm A_2/2                                                        1 (33.3%)           2 (28.6%)            3 (30%)   
#&gt; 
#&gt;   trm A_1/2                                                        1 (33.3%)           1 (14.3%)            2 (20%)   
#&gt; 
#&gt; cl B
#&gt;   Total number of patients with at least one adverse event         1 (33.3%)           3 (42.9%)            4 (40%)   
#&gt; 
#&gt;   Total number of events                                               1                   4                   5      
#&gt; 
#&gt;   trm B_2/3                                                        1 (33.3%)           2 (28.6%)            3 (30%)   
#&gt; 
#&gt;   trm B_1/3                                                            0               1 (14.3%)            1 (10%)   
#&gt; 
#&gt;   trm B_3/3                                                            0               1 (14.3%)            1 (10%)   
#&gt; 
#&gt; cl C
#&gt;   Total number of patients with at least one adverse event         1 (33.3%)           1 (14.3%)            2 (20%)   
#&gt; 
#&gt;   Total number of events                                               1                   1                   2      
#&gt; 
#&gt;   trm C_1/1                                                        1 (33.3%)           1 (14.3%)            2 (20%)   </div><div class='input'>
<span class='co'># Simple example 2</span>

<span class='fu'>library</span>(<span class='no'>dplyr</span>)
<span class='fu'>library</span>(<span class='no'>rtables</span>)
<span class='fu'>library</span>(<span class='no'>random.cdisc.data</span>)


<span class='no'>data</span> <span class='kw'>&lt;-</span> <span class='fu'><a href='http://dplyr.tidyverse.org/reference/join.html'>left_join</a></span>(<span class='fu'><a href='http://www.rdocumentation.org/packages/random.cdisc.data/topics/radam'>radam</a></span>(<span class='st'>"AAE"</span>, <span class='kw'>N</span><span class='kw'>=</span><span class='fl'>10</span>),<span class='fu'><a href='http://www.rdocumentation.org/packages/random.cdisc.data/topics/radam'>radam</a></span>(<span class='st'>"ADSL"</span>, <span class='kw'>N</span><span class='kw'>=</span><span class='fl'>10</span>))</div><div class='output co'>#&gt; <span class='message'>Joining, by = c("STUDYID", "USUBJID")</span></div><div class='input'>
<span class='no'>tbl4</span> <span class='kw'>&lt;-</span> <span class='fu'>t_ae</span>(
  <span class='kw'>class</span> <span class='kw'>=</span> <span class='no'>data</span>$<span class='no'>AEBODSYS</span>,
  <span class='kw'>term</span> <span class='kw'>=</span>  <span class='no'>data</span>$<span class='no'>AEDECOD</span>,
  <span class='kw'>id</span> <span class='kw'>=</span> <span class='no'>data</span>$<span class='no'>USUBJID</span>,
  <span class='kw'>col_by</span> <span class='kw'>=</span> <span class='fu'>factor</span>(<span class='no'>data</span>$<span class='no'>ARM</span>),
  <span class='kw'>total</span> <span class='kw'>=</span> <span class='st'>"None"</span>,
  <span class='kw'>sort_by</span> <span class='kw'>=</span> <span class='st'>"alphabetical"</span>
)

<span class='no'>tbl4</span></div><div class='output co'>#&gt; MedDRA System Organ Class                                                    ARM A            ARM B            None   
#&gt;   MedDRA Preferred Term                                                      (N=5)            (N=5)           (N=10)  
#&gt; ----------------------------------------------------------------------------------------------------------------------
#&gt; Total number of patients with at least one adverse event                   5 (100%)         5 (100%)         10 (100%)
#&gt; 
#&gt; Overall total number of events                                                34               20               54    
#&gt; Blood and lymphatic system disorders
#&gt;   Total number of patients with at least one adverse event                     0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       0                1                1    
#&gt; 
#&gt;   Blood disorder                                                               0             1 (20%)          1 (10%) 
#&gt; 
#&gt; Cardiac disorders
#&gt;   Total number of patients with at least one adverse event                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       1                0                1    
#&gt; 
#&gt;   Tricuspid valve sclerosis                                                 1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Congenital, familial and genetic disorders
#&gt;   Total number of patients with at least one adverse event                  3 (60%)          1 (20%)          4 (40%) 
#&gt; 
#&gt;   Total number of events                                                       4                1                5    
#&gt; 
#&gt;   Congenital aortic dilatation                                                 0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Congenital cystic disease of liver                                        1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Craniotabes                                                               1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Enteric duplication                                                       1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Tibial agenesis                                                           1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Endocrine disorders
#&gt;   Total number of patients with at least one adverse event                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       1                0                1    
#&gt; 
#&gt;   Emphysematous pyelonephritis                                              1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Gastrointestinal disorders
#&gt;   Total number of patients with at least one adverse event                     0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       0                1                1    
#&gt; 
#&gt;   Abscess intestinal                                                           0             1 (20%)          1 (10%) 
#&gt; 
#&gt; General disorders and administration site conditions
#&gt;   Total number of patients with at least one adverse event                  1 (20%)          1 (20%)          2 (20%) 
#&gt; 
#&gt;   Total number of events                                                       1                1                2    
#&gt; 
#&gt;   Catheter site oedema                                                         0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Membrane stabilising effect                                               1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Immune system disorders
#&gt;   Total number of patients with at least one adverse event                  1 (20%)          1 (20%)          2 (20%) 
#&gt; 
#&gt;   Total number of events                                                       1                1                2    
#&gt; 
#&gt;   Dermatomyositis                                                              0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Myasthenia gravis crisis                                                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Infections and infestations
#&gt;   Total number of patients with at least one adverse event                  3 (60%)          1 (20%)          4 (40%) 
#&gt; 
#&gt;   Total number of events                                                       5                1                6    
#&gt; 
#&gt;   Gallbladder empyema                                                       1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Mucormycosis                                                              1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Pleural infection                                                         1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Retroperitoneal infection                                                 1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Tuberculosis of genitourinary system                                         0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Viral rash                                                                1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Injury, poisoning and procedural complications
#&gt;   Total number of patients with at least one adverse event                  1 (20%)          1 (20%)          2 (20%) 
#&gt; 
#&gt;   Total number of events                                                       1                1                2    
#&gt; 
#&gt;   Instillation site oedema                                                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Ligament rupture                                                             0             1 (20%)          1 (10%) 
#&gt; 
#&gt; Investigations
#&gt;   Total number of patients with at least one adverse event                  3 (60%)          2 (40%)          5 (50%) 
#&gt; 
#&gt;   Total number of events                                                       5                4                9    
#&gt; 
#&gt;   Base excess positive                                                      1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Biopsy small intestine abnormal                                              0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Biopsy tongue normal                                                      1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Crossmatch incompatible                                                      0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Enzyme level test                                                         1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Human herpes virus 8 test                                                    0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Skin test negative                                                        1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Urine copper                                                                 0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Urobilinogen faeces normal                                                1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Musculoskeletal and connective tissue disorders
#&gt;   Total number of patients with at least one adverse event                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       1                0                1    
#&gt; 
#&gt;   Muscle contusion                                                          1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Neoplasms benign, malignant and unspecified (incl cysts and polyps)
#&gt;   Total number of patients with at least one adverse event                  3 (60%)          2 (40%)          5 (50%) 
#&gt; 
#&gt;   Total number of events                                                       4                2                6    
#&gt; 
#&gt;   Adult T-cell lymphoma/leukaemia stage IV                                     0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Congenital melanocytic naevus                                                0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Liver carcinoma ruptured                                                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Malignant neoplasm of thymus                                              1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Paranasal sinus and nasal cavity malignant neoplasm stage 0               1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Urinary bladder polyp                                                     1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Nervous system disorders
#&gt;   Total number of patients with at least one adverse event                  4 (80%)          1 (20%)          5 (50%) 
#&gt; 
#&gt;   Total number of events                                                       4                1                5    
#&gt; 
#&gt;   Cerebral reperfusion injury                                               1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Choriomeningitis lymphocytic                                              1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Excessive eye blinking                                                       0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Exertional headache                                                       1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Prosopagnosia                                                             1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Psychiatric disorders
#&gt;   Total number of patients with at least one adverse event                  1 (20%)          1 (20%)          2 (20%) 
#&gt; 
#&gt;   Total number of events                                                       1                1                2    
#&gt; 
#&gt;   Somatic symptom disorder                                                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Tourette's disorder                                                          0             1 (20%)          1 (10%) 
#&gt; 
#&gt; Renal and urinary disorders
#&gt;   Total number of patients with at least one adverse event                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       1                0                1    
#&gt; 
#&gt;   Alkaptonuria                                                              1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Reproductive system and breast disorders
#&gt;   Total number of patients with at least one adverse event                     0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       0                1                1    
#&gt; 
#&gt;   Bleeding anovulatory                                                         0             1 (20%)          1 (10%) 
#&gt; 
#&gt; Respiratory, thoracic and mediastinal disorders
#&gt;   Total number of patients with at least one adverse event                     0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       0                1                1    
#&gt; 
#&gt;   Hypopharyngeal cancer stage III                                              0             1 (20%)          1 (10%) 
#&gt; 
#&gt; Skin and subcutaneous tissue disorders
#&gt;   Total number of patients with at least one adverse event                  2 (40%)          2 (40%)          4 (40%) 
#&gt; 
#&gt;   Total number of events                                                       2                2                4    
#&gt; 
#&gt;   Harlequin syndrome                                                           0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Nail pitting                                                              1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Skin sensitisation                                                           0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Vaccination site eczema                                                   1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Surgical and medical procedures
#&gt;   Total number of patients with at least one adverse event                  1 (20%)             0             1 (10%) 
#&gt; 
#&gt;   Total number of events                                                       1                0                1    
#&gt; 
#&gt;   Colporrhaphy                                                              1 (20%)             0             1 (10%) 
#&gt; 
#&gt; Vascular disorders
#&gt;   Total number of patients with at least one adverse event                  1 (20%)          1 (20%)          2 (20%) 
#&gt; 
#&gt;   Total number of events                                                       1                1                2    
#&gt; 
#&gt;   Instillation site thrombosis                                                 0             1 (20%)          1 (10%) 
#&gt; 
#&gt;   Necrotising herpetic retinopathy                                          1 (20%)             0             1 (10%) </div><div class='input'>
<span class='no'>data</span> <span class='kw'>&lt;-</span> <span class='fu'>read_bce</span>(<span class='st'>"/opt/BIOSTAT/home_ext2/qit3/cdt70194/go39733/libraries/adae.sas7bdat"</span>)</div><div class='output co'>#&gt; <span class='error'>Error in read_bce("/opt/BIOSTAT/home_ext2/qit3/cdt70194/go39733/libraries/adae.sas7bdat"): could not find function "read_bce"</span></div><div class='input'>
<span class='no'>tbl5</span> <span class='kw'>&lt;-</span> <span class='fu'>t_ae</span>(
  <span class='kw'>class</span> <span class='kw'>=</span> <span class='no'>data</span>$<span class='no'>AEBODSYS</span>,
  <span class='kw'>term</span> <span class='kw'>=</span>  <span class='no'>data</span>$<span class='no'>AEDECOD</span>,
  <span class='kw'>id</span> <span class='kw'>=</span> <span class='no'>data</span>$<span class='no'>USUBJID</span>,
  <span class='kw'>col_by</span> <span class='kw'>=</span> <span class='fu'>factor</span>(<span class='no'>data</span>$<span class='no'>ARM</span>)
)

<span class='no'>tbl5</span></div><div class='output co'>#&gt; MedDRA System Organ Class                                                     ARM A               ARM B            All Patients
#&gt;   MedDRA Preferred Term                                                       (N=5)               (N=5)               (N=10)   
#&gt; -------------------------------------------------------------------------------------------------------------------------------
#&gt; Total number of patients with at least one adverse event                     5 (100%)            5 (100%)           10 (100%)  
#&gt; 
#&gt; Overall total number of events                                                  34                  20                  54     
#&gt; Investigations
#&gt;   Total number of patients with at least one adverse event                   3 (60%)             2 (40%)             5 (50%)   
#&gt; 
#&gt;   Total number of events                                                        5                   4                   9      
#&gt; 
#&gt;   Base excess positive                                                       1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Biopsy small intestine abnormal                                               0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Biopsy tongue normal                                                       1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Crossmatch incompatible                                                       0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Enzyme level test                                                          1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Human herpes virus 8 test                                                     0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Skin test negative                                                         1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Urine copper                                                                  0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Urobilinogen faeces normal                                                 1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Neoplasms benign, malignant and unspecified (incl cysts and polyps)
#&gt;   Total number of patients with at least one adverse event                   3 (60%)             2 (40%)             5 (50%)   
#&gt; 
#&gt;   Total number of events                                                        4                   2                   6      
#&gt; 
#&gt;   Adult T-cell lymphoma/leukaemia stage IV                                      0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Congenital melanocytic naevus                                                 0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Liver carcinoma ruptured                                                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Malignant neoplasm of thymus                                               1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Paranasal sinus and nasal cavity malignant neoplasm stage 0                1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Urinary bladder polyp                                                      1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Nervous system disorders
#&gt;   Total number of patients with at least one adverse event                   4 (80%)             1 (20%)             5 (50%)   
#&gt; 
#&gt;   Total number of events                                                        4                   1                   5      
#&gt; 
#&gt;   Cerebral reperfusion injury                                                1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Choriomeningitis lymphocytic                                               1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Excessive eye blinking                                                        0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Exertional headache                                                        1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Prosopagnosia                                                              1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Congenital, familial and genetic disorders
#&gt;   Total number of patients with at least one adverse event                   3 (60%)             1 (20%)             4 (40%)   
#&gt; 
#&gt;   Total number of events                                                        4                   1                   5      
#&gt; 
#&gt;   Congenital aortic dilatation                                                  0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Congenital cystic disease of liver                                         1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Craniotabes                                                                1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Enteric duplication                                                        1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Tibial agenesis                                                            1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Infections and infestations
#&gt;   Total number of patients with at least one adverse event                   3 (60%)             1 (20%)             4 (40%)   
#&gt; 
#&gt;   Total number of events                                                        5                   1                   6      
#&gt; 
#&gt;   Gallbladder empyema                                                        1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Mucormycosis                                                               1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Pleural infection                                                          1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Retroperitoneal infection                                                  1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Tuberculosis of genitourinary system                                          0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Viral rash                                                                 1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Skin and subcutaneous tissue disorders
#&gt;   Total number of patients with at least one adverse event                   2 (40%)             2 (40%)             4 (40%)   
#&gt; 
#&gt;   Total number of events                                                        2                   2                   4      
#&gt; 
#&gt;   Harlequin syndrome                                                            0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Nail pitting                                                               1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Skin sensitisation                                                            0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Vaccination site eczema                                                    1 (20%)                0                1 (10%)   
#&gt; 
#&gt; General disorders and administration site conditions
#&gt;   Total number of patients with at least one adverse event                   1 (20%)             1 (20%)             2 (20%)   
#&gt; 
#&gt;   Total number of events                                                        1                   1                   2      
#&gt; 
#&gt;   Catheter site oedema                                                          0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Membrane stabilising effect                                                1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Immune system disorders
#&gt;   Total number of patients with at least one adverse event                   1 (20%)             1 (20%)             2 (20%)   
#&gt; 
#&gt;   Total number of events                                                        1                   1                   2      
#&gt; 
#&gt;   Dermatomyositis                                                               0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Myasthenia gravis crisis                                                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Injury, poisoning and procedural complications
#&gt;   Total number of patients with at least one adverse event                   1 (20%)             1 (20%)             2 (20%)   
#&gt; 
#&gt;   Total number of events                                                        1                   1                   2      
#&gt; 
#&gt;   Instillation site oedema                                                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Ligament rupture                                                              0                1 (20%)             1 (10%)   
#&gt; 
#&gt; Psychiatric disorders
#&gt;   Total number of patients with at least one adverse event                   1 (20%)             1 (20%)             2 (20%)   
#&gt; 
#&gt;   Total number of events                                                        1                   1                   2      
#&gt; 
#&gt;   Somatic symptom disorder                                                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Tourette's disorder                                                           0                1 (20%)             1 (10%)   
#&gt; 
#&gt; Vascular disorders
#&gt;   Total number of patients with at least one adverse event                   1 (20%)             1 (20%)             2 (20%)   
#&gt; 
#&gt;   Total number of events                                                        1                   1                   2      
#&gt; 
#&gt;   Instillation site thrombosis                                                  0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Necrotising herpetic retinopathy                                           1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Blood and lymphatic system disorders
#&gt;   Total number of patients with at least one adverse event                      0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        0                   1                   1      
#&gt; 
#&gt;   Blood disorder                                                                0                1 (20%)             1 (10%)   
#&gt; 
#&gt; Cardiac disorders
#&gt;   Total number of patients with at least one adverse event                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        1                   0                   1      
#&gt; 
#&gt;   Tricuspid valve sclerosis                                                  1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Endocrine disorders
#&gt;   Total number of patients with at least one adverse event                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        1                   0                   1      
#&gt; 
#&gt;   Emphysematous pyelonephritis                                               1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Gastrointestinal disorders
#&gt;   Total number of patients with at least one adverse event                      0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        0                   1                   1      
#&gt; 
#&gt;   Abscess intestinal                                                            0                1 (20%)             1 (10%)   
#&gt; 
#&gt; Musculoskeletal and connective tissue disorders
#&gt;   Total number of patients with at least one adverse event                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        1                   0                   1      
#&gt; 
#&gt;   Muscle contusion                                                           1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Renal and urinary disorders
#&gt;   Total number of patients with at least one adverse event                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        1                   0                   1      
#&gt; 
#&gt;   Alkaptonuria                                                               1 (20%)                0                1 (10%)   
#&gt; 
#&gt; Reproductive system and breast disorders
#&gt;   Total number of patients with at least one adverse event                      0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        0                   1                   1      
#&gt; 
#&gt;   Bleeding anovulatory                                                          0                1 (20%)             1 (10%)   
#&gt; 
#&gt; Respiratory, thoracic and mediastinal disorders
#&gt;   Total number of patients with at least one adverse event                      0                1 (20%)             1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        0                   1                   1      
#&gt; 
#&gt;   Hypopharyngeal cancer stage III                                               0                1 (20%)             1 (10%)   
#&gt; 
#&gt; Surgical and medical procedures
#&gt;   Total number of patients with at least one adverse event                   1 (20%)                0                1 (10%)   
#&gt; 
#&gt;   Total number of events                                                        1                   0                   1      
#&gt; 
#&gt;   Colporrhaphy                                                               1 (20%)                0                1 (10%)   </div><div class='input'>
</div></pre>
  </div>
  <div class="col-md-3 hidden-xs hidden-sm" id="sidebar">
    <h2>Contents</h2>
    <ul class="nav nav-pills nav-stacked">
      <li><a href="#arguments">Arguments</a></li>
      
      <li><a href="#value">Value</a></li>
      
      <li><a href="#examples">Examples</a></li>
    </ul>

    <h2>Author</h2>
    
Carolyn Zhang

  </div>
</div>

      <footer>
      <div class="copyright">
  <p>Developed by Mika Maekinen, Adrian Waddell, Chendi Liao, Nina Qi, Carolyn Zhang.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="http://pkgdown.r-lib.org/">pkgdown</a>.</p>
</div>

      </footer>
   </div>

  

  </body>
</html>

